Amgen Business Development

Amgen Business Development is the corporate venture capital arm of Amgen Inc., focusing on investments in biotechnology and life sciences companies. The team brings together deep scientific, financial, deal, partnership, and integration expertise to identify and support innovative companies that align with Amgen's strategic interests. Their investments aim to advance Amgen's mission of delivering innovative medicines to patients worldwide. The investment strategy encompasses a broad range of stages, from early-stage startups to more mature companies, with investment sizes typically ranging from $5 million to $50 million. Geographically, Amgen Business Development targets regions including the United States, Europe, Asia, Australia, Canada, Japan, South Korea, China, India, Brazil, Mexico, Argentina, Chile, Colombia, Peru, South Africa, Egypt, Saudi Arabia, United Arab Emirates, and Israel. Industries of interest include biotechnology, pharmaceuticals, healthcare, medical devices, diagnostics, digital health, genomics, immunology, oncology, cardiovascular, neuroscience, rare diseases, regenerative medicine, cell therapy, and gene therapy. This diverse focus reflects Amgen's commitment to advancing science and improving patient outcomes across a wide array of therapeutic areas.

Innovative technologies, Strong scientific evidence, Alignment with Amgen's strategic interests, Experienced management teams, Scalable business models, Potential for significant patient impact